Search the Newsreel

Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX

Flputnam Investment Management Co. has acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), purchasing 40,116 shares valued at approximately $19.93 million during the second quarter. Other institutional investors have also adjusted their holdings in the pharmaceutical company. Analyst ratings for VRTX are generally …

Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Global Retirement Partners LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during the second quarter, purchasing 3,925 shares valued at approximately $1,950,000. Several other institutional investors also adjusted their holdings in the pharmaceutical company. Vertex Pharmaceuticals has a market capitalization of $128.36 …

Prostarm Info Systems Q1FY27 profit jumps 151% to ₹45.8 crore

Neuren Pharmaceuticals (ASX:NEU) Shares in Focus as DAYBUE Growth Supports Higher Royalty Outlook

Chase Investment Counsel Corp Makes New $2.03 Million Investment in Sprouts Farmers Market, Inc. $SFM

Chase Investment Counsel Corp initiated a new position in Sprouts Farmers Market, Inc. (NASDAQ:SFM) during the second quarter, investing approximately $2.03 million by purchasing 24,000 shares. This comes as Sprouts Farmers Market reported strong Q2 earnings with EPS of $1.37 and revenue of $2.33 …

Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN

Focus Partners Advisor Solutions LLC recently invested $1.35 million in Regeneron Pharmaceuticals, acquiring 2,165 shares during the second quarter. Regeneron reported strong quarterly results, beating analyst estimates with EPS of $14.29 and revenue of $4.29 billion, marking a 16.7% year-over-year increase. Despite potential legal …

Gland Pharma Q1FY27 profit up 47% to ₹3,170 crore on strong CDMO growth

Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook

Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD

Empowered Funds LLC has made a new investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), acquiring 48,982 shares valued at approximately $1.09 million. This comes as institutional investors hold 96.71% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target …

NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE

Bank of America Corp DE significantly increased its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 84.4% in the first quarter, now holding 847,089 shares valued at $27.1 million. Despite beating revenue expectations, NewAmsterdam Pharma reported a quarterly loss that missed analyst estimates, leading …

AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

AMG National Trust Bank has made a new $1.22 million investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by purchasing 1,956 shares. This investment comes amidst various other hedge funds adjusting their positions in the biopharmaceutical company, which recently reported strong quarterly earnings, beating analyst estimates, …

Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M

* Cue Biopharma press release [https://seekingalpha.com/pr/20620099-cue-biopharma-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (CUE [https://seekingalpha.com/symbol/CUE]): Q2 GAAP EPS of -$24.14 misses by $22.23. * Revenue of $7.88M (+167.1% Y/Y) beats by $5.78M. * As of June 30, 2026, the company had $17.4 million in cash and cash equivalents after incurring one-time …

Arman Financial Services Share Price Target 2027 to 2030: Analyst

Dimensional Fund Advisors LP Has $239,000 Holdings in HA Sustainable Infrastructure Capital, Inc. $HASI

Dimensional Fund Advisors LP significantly reduced its stake in HA Sustainable Infrastructure Capital, Inc. (NYSE:HASI) by 87.7% in the first quarter, selling 46,209 shares and retaining 6,493 shares valued at $239,000. Despite this, institutional investors and hedge funds still own 96.14% of the stock, …

Empowered Funds LLC Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Empowered Funds LLC significantly increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1,146.4% in the first quarter, now owning 37,430 shares valued at $1.13 million. Institutional investors collectively hold 54.05% of Teva's stock, which opened at $36.78, close to its 52-week high. …

Aarti Pharmalabs Share Price Target 2027 to 2030: Analyst Outlook

2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC

AIGH Capital Management LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 2,486,038 shares valued at approximately $26.7 million in the second quarter, making it their 9th largest holding. Other institutional investors like Norges Bank and Bank of New York Mellon Corp …

SENORES PHARMACEUTICALS L Share Price: 52-Week High Analysis

HC Wainwright Issues Pessimistic Forecast for CNTB Earnings

HC Wainwright has lowered its Q3 2026 EPS estimate for Connect Biopharma (NASDAQ: CNTB) to a loss of $0.30 per share from $0.26, despite the company recently beating Q2 expectations. The firm maintains a "Buy" rating and a $7.00 price target, aligning with the …

Narmada Agrobase Share Price Target 2027 to 2030: Analyst Outlook

Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Inovio Pharmaceuticals (NASDAQ:INO) to a loss of $0.20 per share, up from a previous estimate of $0.24, while maintaining a "Neutral" rating. Analyst sentiment for Inovio is generally positive, with a consensus "Moderate Buy" …

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Rocket Pharmaceuticals (NASDAQ:RCKT) from a "sell" to a "hold" rating, aligning with the broader analyst consensus and an average target price of $8.57. The company's shares opened at $3.47 and have seen significant insider selling totaling $327,220 over the …

Bliss GVS Pharma Share Price Target 2027 to 2030: Analyst Outlook

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

Traws Pharma GAAP EPS of -$0.16 beats by $0.06

* Traws Pharma press release [https://seekingalpha.com/pr/20620150-traws-pharma-reports-q2-2026-financial-results-and-provides-business-highlights] (TRAW [https://seekingalpha.com/symbol/TRAW]): Q2 GAAP EPS of -$0.16 beats by $0.06. * Cash and cash equivalents: As of June 30, 2026, the Company had cash and cash equivalents of $5.0 million, compared to $3.8 million as of December 31, …

Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap?

Alarm.com Holdings (ALRM) Raised 2026 Revenue Guidance, Is The Stock Still Cheap?

BIOMARIN PHARMACEUTICAL INC. : PIPER SANDLER RAISES TARGET PRICE TO $88 FROM $82

Piper Sandler has increased its target price for BioMarin Pharmaceutical Inc. (BMRN.O) from $82 to $88. This adjustment reflects an updated outlook from the analytical firm regarding the biotechnology company's valuation. The news was reported by Reuters.

Radiopharm Theranostics (ASX:RAD) Sets October FDA Meeting as RAD101 Moves Toward Phase 3

Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the Phase 3 trial design for its imaging agent, RAD101. This comes after RAD101 achieved 93% concordance between MRI and PET imaging in its Phase 2b …

Price to earnings forward of Cumberland Pharmaceuticals Inc. – NASDAQ:CPIX

What's Going On With Medexus Pharmaceuticals Inc Stock Sunday?

Enterprise value to revenue forward of CF PharmTech, Inc. Class H – HKEX:2652

Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of investors. This investigation follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. …

Securities Fraud Investigation Into Armstrong World Industries, Inc. (AWI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP has launched a securities fraud investigation into Armstrong World Industries, Inc. (AWI) following a significant drop in its stock price. The investigation stems from the company's Q4 and full-year 2025 financial results, which missed consensus estimates and revealed …

Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds